Successful multifold dose escalation of anti-G D2 monoclonal antibody 3F8 in patients with neuroblastoma: A phase I study
Bone Marrow Neoplasms
Multifold dose escalation of 3F8 is feasible. The findings can be interpreted as compatible with the possibility that HM3F8 can modify toxicity without blunting anti-NB activity. This pain control strategy may help achieve dose escalation with other anti-G(D2) MoAbs.